Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results from a minipig Dose Range Finding (“DRF”) study for Probudur. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate.

Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. This collaboration is for the c.

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative

New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceuticals, Inc.'s (Nasdaq: VRPX) successful $5.0 million public offering of common stock and pre-funded warrants.

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $5.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per pr.

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $5.0 million of shares of the Company's common stock, par value 0.00001 per share, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per.

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

FactSet Research Systems

Blackstone Group

Daqo New Energy

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 Second Quarter Results and Recent Developments.

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at Sidoti Virtual Investor Conference August 14-15.

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Regains Compliance with Nasdaq Minimum Bid Price.

Virpax Regains Compliance with Nasdaq Minimum Bid Price

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday.

Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher

Virpax Pharmaceuticals (NASDAQ: VRPX ) stock is rocketing higher on Wednesday after the preclinical-stage pharmaceutical company announced positive results from a swine model pilot study. Virpax Pharmaceuticals has released results from its swine model study of Probudur.

Why Is Virpax Pharmaceuticals (VRPX) Stock Up 98% Today?

Wednesday, Virpax Pharmaceuticals Inc VRPX released results for a Swine Model pilot study for Probudur, Virpax's long-acting liposomal bupivacaine formulation injected at a wound site to provide immediate and extended pain relief.

Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?

Maxeon Solar Technologies

Srivaru Holding Ltd

Spotting penny stocks with breakout potential requires a keen understanding of several key factors that can indicate imminent growth. One crucial aspect is identifying companies with strong fundamentals.

Spotting Penny Stocks With Breakout Potential, 3 Tips

Shares of Virpax Pharmaceuticals Inc  VRPX are trading higher on Monday on a strong session volume of 22.8 million, as per data from Benzinga Pro.

What's Going With Penny Stock Virpax Pharmaceuticals On Monday?

Virpax Pharmaceuticals (NASDAQ: VRPX ) stock is heading higher on Monday after the preclinical-stage pharmaceutical company secured a new $2.5 million loan. Virpax Pharmaceuticals says that this funding comes from an institutional investor.

Why Is Virpax Pharmaceuticals (VRPX) Stock Up 97% Today?

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding.

Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at 2024 BIO International Convention.

Virpax® Pharmaceuticals to Present at 2024 BIO International Convention

Virpax Pharmaceuticals (NASDAQ: VRPX ) stock is down on Wednesday as the preclinical-stage pharmaceutical company's lackluster earnings report yesterday continues to weigh on its shares today. Considering the stage of the company's drug development pipeline, its lack of revenue for the quarter makes sense.

Why Is Virpax Pharmaceuticals (VRPX) Stock Down 61% Today?

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Pricing of $2.25M Public Offering.

Virpax Announces Pricing of $2.25 Million Public Offering

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 First Quarter Results and Recent Developments.

Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of MTD Study for Probudur. Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief.

Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 Year-End Results.

Virpax Pharmaceuticals Reports 2023 Year-End Results

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price.

Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price

Sorrento Therapeutics Inc

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Preliminary Results of Probudur™ Pilot Study with the U.S. Army Institute of Surgical Research.

News for Virpax Pharmaceuticals Stock (VRPX)